Allen Institute for Immunology Partners with Lilly to Better Understand Autoimmune Disease


In a significant milestone for the Allen Institute for Immunology, a division of the Allen Institute, researchers and staff will collaborate with private industry researchers to aid in the detailed, molecular understanding of disease, in service of developing new treatments and therapies to improve human health.

Specifically, Allen Institute scientists will work with researchers from Eli Lilly and Company (Lilly) to investigate and profile disease state diversity and biomarkers for drug response involving atopic dermatitis (eczema) and rheumatoid arthritis using Allen Institute-developed unique molecular tools and comprehensive bioinformatic analysis techniques.

“Since the creation of the Institute in 2018, we have developed cutting-edge technologies that allow an unprecedented understanding of the human immune system in both health and disease,” said Peter Skene, Ph.D., Director of High Resolution Translational Immunology at the Allen Institute for Immunology. “By partnering with Lilly, we will further our translational mission of impact for patients.”